IBDEI215 ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,34017,0)
 ;;=N01.4^^154^1722^64
 ;;^UTILITY(U,$J,358.3,34017,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34017,1,3,0)
 ;;=3^Rapidly progr neph synd w/ diffus endocaplry prolif glomrlneph
 ;;^UTILITY(U,$J,358.3,34017,1,4,0)
 ;;=4^N01.4
 ;;^UTILITY(U,$J,358.3,34017,2)
 ;;=^5015505
 ;;^UTILITY(U,$J,358.3,34018,0)
 ;;=N01.5^^154^1722^68
 ;;^UTILITY(U,$J,358.3,34018,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34018,1,3,0)
 ;;=3^Rapidly progr neph synd w/ diffuse mesangiocap glomrlneph
 ;;^UTILITY(U,$J,358.3,34018,1,4,0)
 ;;=4^N01.5
 ;;^UTILITY(U,$J,358.3,34018,2)
 ;;=^5015506
 ;;^UTILITY(U,$J,358.3,34019,0)
 ;;=N01.6^^154^1722^63
 ;;^UTILITY(U,$J,358.3,34019,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34019,1,3,0)
 ;;=3^Rapidly progr neph synd w/ dense deposit disease
 ;;^UTILITY(U,$J,358.3,34019,1,4,0)
 ;;=4^N01.6
 ;;^UTILITY(U,$J,358.3,34019,2)
 ;;=^5015507
 ;;^UTILITY(U,$J,358.3,34020,0)
 ;;=N01.7^^154^1722^66
 ;;^UTILITY(U,$J,358.3,34020,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34020,1,3,0)
 ;;=3^Rapidly progr neph synd w/ diffuse crescentic glomrlneph
 ;;^UTILITY(U,$J,358.3,34020,1,4,0)
 ;;=4^N01.7
 ;;^UTILITY(U,$J,358.3,34020,2)
 ;;=^5015508
 ;;^UTILITY(U,$J,358.3,34021,0)
 ;;=N01.8^^154^1722^71
 ;;^UTILITY(U,$J,358.3,34021,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34021,1,3,0)
 ;;=3^Rapidly progr neph synd w/ oth morphologic changes
 ;;^UTILITY(U,$J,358.3,34021,1,4,0)
 ;;=4^N01.8
 ;;^UTILITY(U,$J,358.3,34021,2)
 ;;=^5015509
 ;;^UTILITY(U,$J,358.3,34022,0)
 ;;=N01.9^^154^1722^72
 ;;^UTILITY(U,$J,358.3,34022,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34022,1,3,0)
 ;;=3^Rapidly progr neph synd w/ unsp morphologic changes
 ;;^UTILITY(U,$J,358.3,34022,1,4,0)
 ;;=4^N01.9
 ;;^UTILITY(U,$J,358.3,34022,2)
 ;;=^5015510
 ;;^UTILITY(U,$J,358.3,34023,0)
 ;;=N02.0^^154^1722^80
 ;;^UTILITY(U,$J,358.3,34023,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34023,1,3,0)
 ;;=3^Recurrent & perst hematur w/ minor glomerular abnlt
 ;;^UTILITY(U,$J,358.3,34023,1,4,0)
 ;;=4^N02.0
 ;;^UTILITY(U,$J,358.3,34023,2)
 ;;=^5015511
 ;;^UTILITY(U,$J,358.3,34024,0)
 ;;=N02.1^^154^1722^79
 ;;^UTILITY(U,$J,358.3,34024,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34024,1,3,0)
 ;;=3^Recurrent & perst hematur w/ focal & seg glomerular lesions
 ;;^UTILITY(U,$J,358.3,34024,1,4,0)
 ;;=4^N02.1
 ;;^UTILITY(U,$J,358.3,34024,2)
 ;;=^5015512
 ;;^UTILITY(U,$J,358.3,34025,0)
 ;;=N02.2^^154^1722^77
 ;;^UTILITY(U,$J,358.3,34025,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34025,1,3,0)
 ;;=3^Recurrent & perst hematur w/ diffuse membranous glomrlneph
 ;;^UTILITY(U,$J,358.3,34025,1,4,0)
 ;;=4^N02.2
 ;;^UTILITY(U,$J,358.3,34025,2)
 ;;=^5015513
 ;;^UTILITY(U,$J,358.3,34026,0)
 ;;=N02.3^^154^1722^74
 ;;^UTILITY(U,$J,358.3,34026,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34026,1,3,0)
 ;;=3^Recur & perst hematur w/ diffus mesangial prolif glomrlneph
 ;;^UTILITY(U,$J,358.3,34026,1,4,0)
 ;;=4^N02.3
 ;;^UTILITY(U,$J,358.3,34026,2)
 ;;=^5015514
 ;;^UTILITY(U,$J,358.3,34027,0)
 ;;=N02.4^^154^1722^73
 ;;^UTILITY(U,$J,358.3,34027,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34027,1,3,0)
 ;;=3^Recur & perst hematur w/ diffus endocaplry prolif glomrlneph
 ;;^UTILITY(U,$J,358.3,34027,1,4,0)
 ;;=4^N02.4
 ;;^UTILITY(U,$J,358.3,34027,2)
 ;;=^5015515
 ;;^UTILITY(U,$J,358.3,34028,0)
 ;;=N02.5^^154^1722^78
 ;;^UTILITY(U,$J,358.3,34028,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34028,1,3,0)
 ;;=3^Recurrent & perst hematur w/ diffuse mesangiocap glomrlneph
 ;;^UTILITY(U,$J,358.3,34028,1,4,0)
 ;;=4^N02.5
 ;;^UTILITY(U,$J,358.3,34028,2)
 ;;=^5015516
